Latest Insider Transactions at Tactile Systems Technology Inc (TCMD)
This section provides a real-time view of insider transactions for Tactile Systems Technology Inc (TCMD). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of TACTILE SYSTEMS TECHNOLOGY INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of TACTILE SYSTEMS TECHNOLOGY INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 12
2024
|
Sherri Lee Ferstler Senior VP, Sales |
SELL
Open market or private sale
|
Direct |
1,550
-3.84%
|
$20,150
$13.07 P/Share
|
|
Aug 07
2024
|
Sheri Louise Dodd Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
64,959
+39.71%
|
-
|
|
May 16
2024
|
Elaine M. Birkemeyer Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,041
-4.73%
|
$39,533
$13.68 P/Share
|
|
May 08
2024
|
William W Burke Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,469
+22.65%
|
-
|
|
May 08
2024
|
William W Burke Director |
SELL
Open market or private sale
|
Direct |
2,500
-9.0%
|
$35,000
$14.06 P/Share
|
|
May 08
2024
|
Boyd Vindell Washington Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,469
+35.32%
|
-
|
|
May 08
2024
|
Carmen B Volkart Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,469
+32.62%
|
-
|
|
May 08
2024
|
David Brent Shafer Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,469
+24.23%
|
-
|
|
May 08
2024
|
Raymond Huggenberger Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,469
+20.64%
|
-
|
|
May 08
2024
|
Sheri Louise Dodd Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,469
+23.73%
|
-
|
|
May 08
2024
|
Valerie L. Asbury Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,469
+24.23%
|
-
|
|
May 06
2024
|
Kristie Burns Sr. VP Mktg & Clinical Affairs |
SELL
Open market or private sale
|
Direct |
815
-1.29%
|
$11,410
$14.37 P/Share
|
|
Feb 29
2024
|
Kristie Burns Sr. VP Mktg & Clinical Affairs |
SELL
Open market or private sale
|
Direct |
243
-0.38%
|
$3,645
$15.25 P/Share
|
|
Feb 29
2024
|
Daniel L. Reuvers President and CEO |
SELL
Open market or private sale
|
Direct |
1,396
-0.58%
|
$20,940
$15.25 P/Share
|
|
Feb 27
2024
|
Kristie Burns Sr. VP Mktg & Clinical Affairs |
SELL
Open market or private sale
|
Direct |
1,091
-1.69%
|
$16,365
$15.58 P/Share
|
|
Feb 27
2024
|
Daniel L. Reuvers President and CEO |
SELL
Open market or private sale
|
Direct |
4,689
-1.92%
|
$70,335
$15.6 P/Share
|
|
Feb 26
2024
|
Kristie Burns Sr. VP Mktg & Clinical Affairs |
SELL
Open market or private sale
|
Direct |
2,015
-3.08%
|
$30,225
$15.9 P/Share
|
|
Feb 26
2024
|
Daniel L. Reuvers President and CEO |
SELL
Open market or private sale
|
Direct |
6,239
-2.49%
|
$93,585
$15.81 P/Share
|
|
Feb 24
2024
|
Elaine M. Birkemeyer Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,848
+4.24%
|
-
|
|
Feb 24
2024
|
Kristie Burns Sr. VP Mktg & Clinical Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
11,762
+8.3%
|
-
|
|
Feb 24
2024
|
Daniel L. Reuvers President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
58,030
+10.45%
|
-
|
|
Feb 23
2024
|
Kristie Burns Sr. VP Mktg & Clinical Affairs |
SELL
Open market or private sale
|
Direct |
2,249
-4.02%
|
$31,486
$14.8 P/Share
|
|
Feb 23
2024
|
Daniel L. Reuvers President and CEO |
SELL
Open market or private sale
|
Direct |
5,378
-2.72%
|
$75,292
$14.85 P/Share
|
|
Feb 21
2024
|
Kristie Burns Sr. VP Mktg & Clinical Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
19,452
+25.78%
|
-
|
|
Feb 21
2024
|
Daniel L. Reuvers President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
72,046
+26.71%
|
-
|
|
Feb 21
2024
|
Elaine M. Birkemeyer Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,420
+34.52%
|
-
|
|
Feb 21
2024
|
Sherri Lee Ferstler Senior VP, Sales |
BUY
Grant, award, or other acquisition
|
Direct |
21,613
+34.9%
|
-
|
|
Nov 08
2023
|
Boyd Vindell Washington Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,700
+50.0%
|
-
|
|
Aug 09
2023
|
Sherri Lee Ferstler Senior VP, Sales |
BUY
Grant, award, or other acquisition
|
Direct |
18,701
+50.0%
|
-
|
|
Aug 07
2023
|
Daniel L. Reuvers President and CEO |
SELL
Open market or private sale
|
Direct |
1,062
-0.84%
|
$21,240
$20.53 P/Share
|
|
May 12
2023
|
William W Burke Director |
SELL
Open market or private sale
|
Direct |
4,400
-13.68%
|
$92,400
$21.86 P/Share
|
|
May 10
2023
|
Elaine M. Birkemeyer Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
29,068
+50.0%
|
-
|
|
May 08
2023
|
William W Burke Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,737
+19.39%
|
-
|
|
May 08
2023
|
Valerie L. Asbury Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,737
+25.78%
|
-
|
|
May 08
2023
|
Raymond Huggenberger Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,737
+20.63%
|
-
|
|
May 08
2023
|
Sheri Louise Dodd Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,737
+25.02%
|
-
|
|
May 08
2023
|
Carmen B Volkart Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,737
+40.96%
|
-
|
|
May 08
2023
|
David Brent Shafer Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,737
+25.78%
|
-
|
|
May 08
2023
|
Eric Pauls Senior VP, Sales |
SELL
Open market or private sale
|
Direct |
550
-1.83%
|
$9,900
$18.55 P/Share
|
|
May 08
2023
|
Kristie Burns Sr. VP Mktg & Clinical Affairs |
SELL
Open market or private sale
|
Direct |
786
-2.1%
|
$14,148
$18.65 P/Share
|
|
Mar 01
2023
|
Brent Moen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,391
-2.77%
|
$19,474
$14.1 P/Share
|
|
Feb 28
2023
|
Brent Moen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
251
-0.5%
|
$3,514
$14.58 P/Share
|
|
Feb 28
2023
|
Daniel L. Reuvers President and CEO |
SELL
Open market or private sale
|
Direct |
700
-0.55%
|
$9,800
$14.56 P/Share
|
|
Feb 28
2023
|
Eric Pauls Senior VP, Sales |
SELL
Open market or private sale
|
Direct |
72
-0.24%
|
$1,008
$14.54 P/Share
|
|
Feb 28
2023
|
Kristie Burns Sr. VP Mktg & Clinical Affairs |
SELL
Open market or private sale
|
Direct |
135
-0.36%
|
$1,890
$14.58 P/Share
|
|
Feb 27
2023
|
Brent Moen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,801
-7.01%
|
$57,015
$15.36 P/Share
|
|
Feb 27
2023
|
Daniel L. Reuvers President and CEO |
SELL
Open market or private sale
|
Direct |
6,387
-4.77%
|
$95,805
$15.27 P/Share
|
|
Feb 27
2023
|
Eric Pauls Senior VP, Sales |
SELL
Open market or private sale
|
Direct |
1,401
-4.44%
|
$21,015
$15.33 P/Share
|
|
Feb 27
2023
|
Kristie Burns Sr. VP Mktg & Clinical Affairs |
SELL
Open market or private sale
|
Direct |
2,162
-5.45%
|
$32,430
$15.39 P/Share
|
|
Feb 25
2023
|
Brent Moen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,304
+4.08%
|
-
|